INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Cytokinetics (CYTK) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against Cytokinetics, alleging that the company misrepresented its expectations for FDA approval of aficamten and failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [1] - The lawsuit claims that Cytokinetics indicated an expectation for FDA approval in the second half of 2025, based on a PDUFA date of September 26, 2025 [1] - The lawsuit is aimed at shareholders who purchased shares between December 27, 2023, and May 6, 2025, and experienced significant losses [2] Legal Information - The deadline for shareholders to request to be appointed as lead plaintiff in the case is November 17, 2025 [3] - Holzer & Holzer, LLC is the law firm representing the shareholders, known for its vigorous representation in securities litigation [3]